BMS Reinforces Leadership in oHCM with New Camzyos Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26) ...

Myqorzo (aficamten) is an oral medicine used for people with obstructive hypertrophic cardiomyopathy (oHCM). Hypertrophic cardiomyopathy (HCM) is an inherited condition (passed down in families) that ...

Positive results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE: ...

Cytokinetics, Incorporated CYTK announced that the European Commission (EC) has approved Myqorzo (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets, for the treatment of adult patients with symptomatic ...

Aficamten offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed aficamten's efficacy in improving exercise ...

Cytokinetics, Incorporated (CYTK) is gearing up to complete its rolling NDA submission of aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy [oHCM] in Q3 of 2024.

Database-linked claims identified oHCM via ≥2 diagnosis codes and evaluated MACE, medication use, HCRU, and costs across variable, 1-year, and 5-year follow-up windows. Stroke incidence was higher in ...

Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26) Positive Phase 3 results of SCOUT ...

Positive results support the potential for Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescent oHCM “The SCOUT-HCM study is important for patients and the field of ...

Positive Phase 3 results of SCOUT-HCM trial highlight potential of Camzyos to be the first cardiac myosin inhibitor for the treatment of adolescents with symptomatic obstructive hypertrophic ...